We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Felcana is a patented Eco-system of connected devices: Helix, Home Hub, Micro-Location Beacons and the Felcana application which work together to monitor the pet's (cat or dogs) well-being. This Digital Pet Health Platform tracks pet's behaviour and provides the vet, rich data leading to faster diagnosis and faster treatment. Felcana has been developed by a world-class team of vets and engineers and, it has been designed and tested by using the latest materials, designs, and techniques. Felcana has won the Design Spark Award in 2017. It is making unique partnerships with leading pet industries and the UK's largest pet health plan provider, the world's top-ranked vet school and The Royal Veterinary College. The new investment will enable it to grow consumer reach and accelerate its sales.
days to go: Expired investment: £343,926
The GP Service is a web and application-based platform that provides private consultations for patients across the UK. The aim is to provide a safe and easy journey for individuals who are looking for private medical treatment at their convenience and at an affordable cost. They have established a connection with over 1600 pharmacies across the UK. They have an excellent 5-star trust pilot rating and also are 1st Private Online Provider which has access to NHS Medical Records. With the proceeds, the company will scale the enterprise offering, increase brand awareness and also launch additional revenue opportunities.

Pitch Rated

77%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £907,540
We created FlyFit with the aim to change the way people travel. Air travel can be stressful, lonely, and unhealthy. On top of this, with average layovers of 2+ hours, flight delays, and hours waiting in security, there is too much unproductive time in airports with limited healthy options to choose from.
days to go: Expired investment: £500,060
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.   
days to go: Expired investment: £30,564
Milbotix, a healthtech start-up, supported by the Alzheimer's Society and the UK Dementia Research Institute, is driven by its innovative product SmartSocks™. This wearable technology aims to assist individuals with dementia facing communication challenges and their caregivers. Globally, the number of people with dementia is increasing significantly, reaching 78 million by 2030 and 139 million by 2050. Half of those diagnosed with dementia encounter challenging behavioral symptoms due to distress. Early distress management not only enhances well-being but also helps prevent escalating behavioral issues. SmartSocks™ utilize sensors and artificial intelligence to notify dementia caregivers about early signs of pain and anxiety in their patients.
days to go: Expired investment: £220,780
&SISTERS is a femcare company offering products that are hypoallergenic, pH-neutral and free from chlorine, pesticides & perfumes. It has sold 225,000+ certified organic cotton period products, directly to 300+ customers. The company has many listed retailers including Feel Unique, Farmdrop and Triyoga and exports to many countries including Asia and Europe. In January 2020, &SISTERS is planning to launch a new paper-wrapped naked tampon®. With the proceeds, the company will expand the product range, expand the team, raise awareness and accelerate sales.
days to go: Expired investment: £199,630
Actve is on a mission to build a platform that caters to the new wave of instructors, social media influencers and athletes becoming online content creators. The company aspires to help creators earn an income and build a subscription business. Actve asserts that it caters to a variety of creator needs allowing them to live-stream their workouts, offer guided programs to customers, or use Actve's software to manage their clients. The company aims to become a contender in the digital fitness market that is projected to be worth £21 billion by 2022. It aims to launch its platform in September 2021. Actve will use the investment to develop its platform, hire key staff, build its user base, and work towards becoming an industry champion for fitness creators.

Pitch Rated

67%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £166,670
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph